Business
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.1
About this update from Camurus Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"First subcutaneous, once-monthly octreotide for treatment of acromegaly","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"For convenient self-administration with a pre-filled autoinjector pen","length":69,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":140,"olType":false},{"type":"text","content":"LUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.1 ","length":335,"tagName":"p"},{"type":"text","content":""Oczyesa is the first approved once-monthly, subcutaneous octreotide treatment for patients with acromegaly", says Fredrik Tiberg, President & CEO, CSO at Camurus. "We look forward to making this new treatment option, designed for convenient self-administration, available to eligible patients in the EU as soon as possible."","length":349,"tagName":"p"},{"type":"text","content":"Acromegaly is a rare, serious, and chronic disease characterized by excessive growth of bone and tissue, resulting in enlarged hands, feet, facial features, and inner organs. Symptoms include fatigue, joint pain, headache, visual field defects, excessive sweating, and paresthesia.2 Patients with uncontrolled acromegaly often experience reduced quality of life and increased mortality risk.3,4 An estimated 70,000 people in the EU are living with acromegaly.5 ","length":460,"tagName":"p"},{"type":"text","content":""Oczyesa is a welcome new treatment option for patients with acromegaly, providing effective disease control and enabling convenient self-administration by patients", says Dr Diego Ferone, Professor in Endocrinology, Head of Department of Internal Medicine at the Ospedale Policlinico San Martino, University of Genova, Italy, and coordinating investigator of the ACROINNOVA program. "Results from the ACROINNOVA clinical program have shown that Oczyesa provides effective and durable biochemical treatment response, as well as improved acromegaly symptom control and quality of life compared to current standard treatment."","length":649,"tagName":"p"},{"type":"text","co...